Fig. 2From: Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patientsctDNA detection at baseline. cfcDNA and ctDNA concentrations, prior palbociclib-fulvestrant treatment initiation, are displayed in copies per ml of plasma extracted. Patients are ranked by decreasing ctDNA concentrations. Gray bars represent cfcDNA concentrations; pink bars represent ctDNA concentrationsBack to article page